Myélome à IgM: 6 observations et revue de la littérature

Gramont, Aimery de; Grosbois, B.; Michaux, Jl.; Peny, A.M.; Pollet, J. P.; Smadja, N; Krulik, M; Debray, J; Bernard, Jean‐François; Monconduit, M.

doi:10.1016/s0248-8663(05)80602-2

Cited by 18 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, IgM myeloma has been described, although it is even rarer than IgD disease, and accounts for approximately 0.5% of cases. 4–8 For example, only 3 of 242 cases fulfilling the criteria of multiple myeloma in 1 series had an IgM monoclonal protein. 4 Published reports have also suggested that IgM myeloma has a poorer prognosis than the more common isotypes.…”

Section: Introductionmentioning

confidence: 99%

“…4–8 For example, only 3 of 242 cases fulfilling the criteria of multiple myeloma in 1 series had an IgM monoclonal protein. 4 Published reports have also suggested that IgM myeloma has a poorer prognosis than the more common isotypes. 5,7 Recently, IgM myeloma has been found to be associated with t(11;14), which represents a translocation between the immunoglobulin heavy chain gene locus on chromosome 14 and cyclin D1 on chromosome 11; 1 case with t(4;14), an unfavorable prognostic factor, has also been reported.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

Reece

Vesole

Shrestha

et al. 2010

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Introduction Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

Reece

Vesole

Shrestha

et al. 2010

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

show abstract

“…Multiple myeloma is a mature B-cell malignancy characterised by a clonal proliferation of pathological plasma cells in the bone marrow. The majority of myelomas secrete IgG or IgA paraproteins or free light chains: true IgM MM is rare and represents a poorly characterised entity which accounts for less than 0.5% of all cases [1] IgM paraproteins are much more frequently associated with other clonal B-cell disorders with WM being by far the most common example [2]. Although IgM myeloma accounts for less than 0.2% of IgM paraproteins [3] it does appear to represent a distinct clinical entity [4].…”

Section: Discussionmentioning

confidence: 99%

IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia

et al. 2008

View full text Add to dashboard Cite

As IgM multiple myeloma is a rare poorly characterised disease entity; there is only limited published data on its clinical, microscopic and immunophenotypic features. We report a 72-year-old man misdiagnosed as Waldenström's macroglobulinemia. Also the diagnosis was further complicated by coexisting chronic lymphocytic leukaemia. Following confirmation of IgM myeloma, in view of the patient's deteriorating clinical condition; he was entered into the UK Medical Research Council Myeloma IX trial where he had partial response to chemotherapy. This case highlights the value of detailed immunophenotypic evaluation when clinical and morphological markers are equivocal.

show abstract

“…El de ki ve ri ler le IgM mye lom lu hasta lar da bir yıl lık ya şam sü re si %82, or ta la ma ya şam sü re si ise 30 ay ola rak be lir til mek te dir. 17,18 WM'li has ta lar da iz le nen he pa to me ga li ve ya len fa de no pa ti nin has ta la rın sa de ce %20-40'ın da oldu ğu dü şü nül dü ğün de, IgM mye lom ile WM ayı rı -mın da kli nik bul gu lar her za man yar dım cı ola mamak ta dır. Bu ne den le li tik lez yon la rın var lı ğı nın MM ta nı sı için spe si fik ol du ğu dü şü nül müş, fa kat li tik lez yo nu ol ma yan MM has ta la rın da ta nı zor luğu or ta ya çık mış tır.…”

Section: Tar Tiş Maunclassified

A Rare Plasma Cell Dyscrasias: IgM Myeloma: Case Report

Sönmez¹,

Çobanoğlu²,

Sönmez³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

ultipl myelom (MM) B lenfositlerin matür formu olan plazma hücrelerinin kontrolsüz ve monoklonal artışıyla karakterize bir hastalıktır. Hastaların çoğunda malign plazma hücrelerinden salgılanan monoklonal karakterde ve genellikle immunoglobulin (Ig) G veya IgA komponenti içinde bulunan paraproteinler serum ve idrarda saptanır. Ö ÖZ ZE ET T Mul tipl mye lom (MM) plaz ma hüc re le ri nin kon trol süz ve klo nal ar tı şı ile ka rak te ri ze ma lign bir B hüc re has ta lı ğı dır. İmmu nog lo bu lin M (IgM) mye lom ise tüm MM has ta la rı nın %0.5'in den daha azın da iz le nen na dir bir len fop ro li fe ra tif has ta lık tır. MM ve Wal dens tröm's mak rog lo bu li ne misi (WM) has ta la rın da iz le ne bi len kli nik ve pa to lo jik bul gu la ra sa hip ola bi len IgM mye lom, MM'nin fark lı bir alt gru bu dur. Bu ne den le IgM mye lom va ka la rı nın WM'den ayı rı mı nı yap mak ge rek klinik se yir ve prog noz, ge rek se te da vi açı sın dan önem li dir. Bu va ka tak di min de, IgM mye lom ta nı sı ko nu lan bir has ta nın kli ni ko-pa to lo jik özel lik le ri li te ra tür eş li ğin de tar tı şıl dı. A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Mul tipl mye lom; im müng lo bu lin M; Wal dens tröm mak rog lo bu li ne mi si A AB BS S T TR RA AC CT T Mul tip le mye lo ma (MM)is a B-cell ma lig nancy cha rac te ri zed by un con trol led clo nal pro li fe ra ti on of ma lig nant plas ma cells. Im mu nog lo bu lin M (IgM) mye lo ma is a ra re lymphop ro life ra ti ve di se a se, ac co un ting for less than 0.5% of all MM ca ses. IgM mye lo ma is a dis tinct subt ype of MM, disp la ying cli ni cal and pat ho lo gic fe a tu res of both MM and Wal dens tröm's mac rog lo bu line mi a (WM). It is im por tant to dis tin gu ish bet we en IgM mye lo ma and WM as they ha ve dis tinct cli ni cal co ur ses and prog no ses, and tre at ment stra te gi es are the re fo re dif fe rent. In this ca se re port, the cli ni co-pat ho lo gic cha rac te ris tics of a pa ti ent di ag no sed as IgM mye lo ma are dis cus sed and the li te ra tu re is re vi e wed.

show abstract

Myélome à IgM: 6 observations et revue de la littérature

Cited by 18 publications

References 24 publications

Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia

A Rare Plasma Cell Dyscrasias: IgM Myeloma: Case Report

Contact Info

Product

Resources

About